Innovations in Keratoconus Diagnosis and Management—Part II

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Ophthalmology".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 1850

Special Issue Editor


E-Mail Website
Guest Editor
Department of Ophthalmology, Keio University, School of Medicine, Tokyo, Japan
Interests: keratoconus; contact lens; refractive surgery; meta-analysis; medical device
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In November 2020, the first volume of the Special Issue “Innovations in Keratoconus Diagnosis and Management” was launched (https://www.mdpi.com/journal/jcm/special_issues/keratoconus_management), in which numerous fascinating papers on the topic of keratoconus were published. We are now pleased to announce that we will be launching the second volume on this topic.

Keratoconus is a progressive, frequently asymmetric, inflammatory corneal thinning disorder characterized by changes in the structure and organization of corneal collagen. This progressive bilateral disease weakens the cornea, resulting in myopia, irregular astigmatism, and central corneal scarring. Accurate corneal imaging is now highly desirable for diagnosing keratoconus, especially in its earlier stages when visual acuity is still good. Modern anterior segment imaging techniques, such as Scheimpflug photography and optical coherence tomography, have significantly improved our ability to identify eyes with keratoconus, as they also provide pachymetric data and posterior corneal curvature measurements. As for keratoconus treatments, corneal cross-linking (CXL) was first introduced as a promising technique to slow or stop disease progression. There have been various modifications to standard CXL, such as increasing the intensity of ultraviolet-A irradiation and shortening the exposure time (accelerated CXL) without altering the total energy delivered. Another modification has been to perform CXL through an intact epithelium (transepithelial CXL) with less discomfort to the patient and reduced postoperative complications. This Special Issue will feature articles on recent developments in keratoconus. We therefore invite researchers to submit original research and review articles on cutting-edge technologies that will contribute to the diagnosis and management of keratoconus.

Dr. Hidenaga Kobashi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • corneal ectasia
  • keratoconus
  • corneal cross-linking
  • Scheimpflug
  • optical coherence tomography

Related Special Issue

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 1334 KiB  
Article
Expression of Tissue Inhibitors of Metalloproteinases (TIMP-1, TIMP-2, TIMP-3, TIMP-4) in Blood Serum of Patients with Keratoconus
by Marta Nowak-Wąs, Paweł Wąs, Zenon Czuba, Romuald Wojnicz and Dorota Wyględowska-Promieńska
J. Clin. Med. 2024, 13(4), 1168; https://doi.org/10.3390/jcm13041168 - 19 Feb 2024
Viewed by 579
Abstract
Background: The etiology of keratoconus is unclear. Current evidence suggests that inflammatory and systemic mechanisms might play a role in its pathophysiology. The proper interaction of proteolytic enzymes—matrix metalloproteinases—and their specific tissue inhibitors (TIMPs) within the cornea is essential in maintaining its structure, [...] Read more.
Background: The etiology of keratoconus is unclear. Current evidence suggests that inflammatory and systemic mechanisms might play a role in its pathophysiology. The proper interaction of proteolytic enzymes—matrix metalloproteinases—and their specific tissue inhibitors (TIMPs) within the cornea is essential in maintaining its structure, transparency and healing processes. The aim of the study was to determine the concentration of the TIMPs TIMP-1, TIMP-2, TIMP-3, and TIMP-4 in the blood serum samples of patients with keratoconus compared to the control group. Methods: The study encompassed 132 patients, of which 83 people constituted the study group and 49 the control group. The concentration of selected TIMPs was determined using the Human Magnetic Luminex® Performance Assay method. Results: In the study group, the concentrations of TIMP-1 and TIMP-3 were statistically significantly reduced, and TIMP-2 and TIMP-4 increased compared to the control group. The analysis of individual TIMPs in terms of their usefulness as potential predictors of keratoconus showed high results of diagnostic sensitivity and specificity for all TIMPs, in particular for TIMP-1 and TIMP-2. Conclusion: The above results may indicate systemic disturbances in the TIMPs regulation among keratoconus patients. High diagnostic sensitivity and specificity of all TIMPs, in particular TIMP-1 and TIMP-2, may confirm their participation in the etiopathogenesis of this disease. Full article
(This article belongs to the Special Issue Innovations in Keratoconus Diagnosis and Management—Part II)
Show Figures

Figure 1

12 pages, 257 KiB  
Article
Impact of Cross-Linking Procedure on Perioperative Quality of Life in Keratoconus Patients
by Susanne Marx-Gross, Angelina Kroell, Daniel Wollschlaeger, Alexander K. Schuster, Jana C. Riedl, Joanna Wasielica-Poslednik and Norbert Pfeiffer
J. Clin. Med. 2023, 12(11), 3833; https://doi.org/10.3390/jcm12113833 - 03 Jun 2023
Viewed by 924
Abstract
Background: To evaluate the effect of crosslinking (CXL) with riboflavin for keratoconus (KC) therapy on quality of life (QoL): comparison of keratoconus patients with and without treatment. Methods: Prospective monocentric study. We recruited patients with progressive KC and with stable disease. Patients with [...] Read more.
Background: To evaluate the effect of crosslinking (CXL) with riboflavin for keratoconus (KC) therapy on quality of life (QoL): comparison of keratoconus patients with and without treatment. Methods: Prospective monocentric study. We recruited patients with progressive KC and with stable disease. Patients with progressive disease received cross-linking treatment; patients with stable disease were monitored. We compared QoL in both groups over 6 months and detected the influence of cross-linking treatment on QoL. QoL was assessed by NEI-VFQ-25, EQ-5D 5L, and EQ-Visual analog scale (VAS). In the evaluation of the Nei VFQ, the subgroups LFVFS and LFSES were calculated. Results: We enrolled 31 eyes of 31 patients in the intervention group and 37 eyes of 37 patients in the control group. Medians with standard deviations (SD) were calculated. All QoL-tests showed equal scores at baseline in both groups. At V2, one day after the treatment, EQ-VAS (56.4), LFVFS (57.4), and EQ5D5L (0.59) were significantly reduced. At V3 (one week after treatment), all results returned to baseline level. LFSES was not affected by the treatment. It remained stable (V2 85.4, V3 84.3). Comparing the baseline scores with the follow-up scores at month 6, we found a significant increase in QoL in all tests in the intervention group. Otherwise, the quality of life in the control group did not change over time. Conclusions: Cross-linking led only to a short-term reduction in QoL. Although the treatment is painful for a few days, no effect on general quality of life LVSES has been demonstrated. QoL already returned to baseline after one week and the patients were not limited anymore. Full article
(This article belongs to the Special Issue Innovations in Keratoconus Diagnosis and Management—Part II)
Back to TopTop